Skip to main content
SpringerLink
Log in

Advances in Vascular Medicine

Vascular Disease in Scleroderma

  • Chapter
  • First Online:
Book cover Advances in Vascular Medicine

  • 888 Accesses

Abstract

Scleroderma is a severe systemic disorder affecting 240 per million of population, characterized by fibrosis of the skin and internal organs, by autoimmune phenomena, and by vascular injury (for review, see1). Scleroderma patients form a heterogeneous group with a very wide spectrum of disease severity. In the most mildly affected individuals, Raynaud’s phenomenon and barely noticeable skin thickening may be the only manifestations of the disease. At the opposite end of the disease spectrum are patients with total skin encasement and life-threatening pulmonary, cardiac, or renal complications.2

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Varga J, Abraham D (2007) Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 117:557-567

    Article  CAS  PubMed  Google Scholar 

  2. Black CM, Stephens CO (1993) Scleroderma-systemic sclerosis. In: Maddison PJ, Isenberg D, Woo P, Glass DN (eds) Oxford Textbook of Rheumatology. Oxford University Press, Oxford, pp 771-789

    Google Scholar 

  3. Subcommittee for scleroderma criteria of the American Rheumatism Association diagnostic and therapeutic criteria committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581-590

    Article  Google Scholar 

  4. LeRoy EC, Black CM, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, Rowell N, Wolheim F (1988) Scleroderma; classification, subsets, and pathogenesis. J Rheumatol 15:202-205

    CAS  PubMed  Google Scholar 

  5. Steen VD, Medsger TA Jr (2007) Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 66:940-944

    Article  PubMed  Google Scholar 

  6. Harris ML, Rosen A (2003) Autoimmunity in scleroderma: the origin, pathogenetic role, and clinical significance of autoantibodies. Curr Opin Rheumatol 15:778-784

    Article  CAS  PubMed  Google Scholar 

  7. Steen VD, Powell DL, Medsger TA Jr (1988) Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 31:196-203

    Article  CAS  PubMed  Google Scholar 

  8. Tan EM, Rodnan GP, Garcia I, Moroi Y, Fritzler MJ, Peebles C (1980) Diversity of antinuclear antibodies in progressive systemic sclerosis: anti-centromere antibody and its relationship to CREST syndrome. Arthritis Rheum 23:617-625

    Article  CAS  PubMed  Google Scholar 

  9. Weiner ES, Earnshaw WC, Senecal JL, Bordwell B, Johnson P, Rothfield NF (1988) Clinical associations of anti-centromere antibodies and antibodies to topoisomerase I: a study of 355 patients. Arthritis Rheum 31:378-385

    Article  CAS  PubMed  Google Scholar 

  10. Catagio LJ, Bernstein RM, Black CM, Hughes GRV, Maddison PJ (1983) Serological markers in progressive systemic sclerosis: clinical correlations. Ann Rheum Dis 42:23-27

    Article  Google Scholar 

  11. Kuwana MJ, Kaburaki J, Mimori T, Tojo T, Homma M (1993) Autoantibody reactive with three classes of RNA polymerases in sera from patients with systemic sclerosis. J Clin Invest 91:1399-1404

    Article  CAS  PubMed  Google Scholar 

  12. Okano Y, Steen VD, Medsger TA Jr (1993) Autoantibody reactive with RNA polymerase III in systemic sclerosis. Ann Intern Med 119:1005-1013

    CAS  PubMed  Google Scholar 

  13. Penn H, Howie AJ, Kingdon EJ, Bunn CC, Stratton RJ, Black CM, Burns A (2007) Denton CP Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM 100:485-494

    Article  CAS  PubMed  Google Scholar 

  14. Reimer G, Rose KM, Scheer U, Tan EM (1987) Autoantibody to RNA polymerase I in scleroderma sera. J Clin Invest 79:65-72

    Article  CAS  PubMed  Google Scholar 

  15. Kahaleh MB (2004) Raynaud phenomenon and the vascular disease in scleroderma. Curr Opin Rheumatol 16:718-722

    Article  PubMed  Google Scholar 

  16. Kahaleh MB, LeRoy EC (1979) Endothelial injury in scleroderma. J Exp Med 149:1326-1335

    Article  CAS  PubMed  Google Scholar 

  17. Harrison NK, Myers AR, Corrin B, Soosay G, Dewar A, Black CM, Du Bois RM (1991) Turner-Warwick M.Structural features of interstitial lung disease in systemic sclerosis. Am Rev Respir Dis 144(3 Pt 1):706-713

    CAS  PubMed  Google Scholar 

  18. Sgonc R, Gruschwitz MS, Dietrich H, Recheis H, Gershwin ME, Wick G (1996) Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest 98(3):785-792

    Article  CAS  PubMed  Google Scholar 

  19. Echberg MR, Nilsson IK, Linell F (1981) Significance of increased factor VIII in early glomerulonephritis. Ann Intern Med 94:482-484

    Google Scholar 

  20. Boneu B, Bierme R, Fournier A, Ponkonner G (1977) Factor VIII complex, fetal growth retardation and toxaemia. Lancet 1:263

    Article  CAS  PubMed  Google Scholar 

  21. Nusinow SR, Federici AB, Zimmerman TS, Curd JG (1984) Increased Von Willebrand factor antigen in the plasma of patients with vasculitis. Arthritis Rheum 27:1405-1409

    Article  CAS  PubMed  Google Scholar 

  22. Drenk F, Deicher HR (1988) Pathophysiological effects of endothelial cytotoxic activity derived from sera of patients with progressive systemic sclerosis. J Rheumatol 15:468-474

    CAS  PubMed  Google Scholar 

  23. Gordon JL, Pottinger BE, Woo P, Rosenbaum J, Black CM (1987) Plasma von Willebrand factor in connective tissue disease. Ann Rheum Dis 46:491-492

    Article  CAS  PubMed  Google Scholar 

  24. Kahaleh MB, Osborn I, LeRoy EC (1981) Increased factor VIII von Willebrand factor antigen and von Willebrand factor activity in scleroderma and Raynaud’s phenomenon. Ann Int Med 94:482-484

    CAS  PubMed  Google Scholar 

  25. Yamane K, Miyauchi T, Suzuki N, Miyauchi T, Yanagisawa M, Goto K, Masaki T (1991) Elevated levels of plasma endothelin-1 in systemic sclerosis. Arthritis Rheum 34:243-244

    Article  CAS  PubMed  Google Scholar 

  26. Vancheeswaran R, Magoulas T, Efrat G, Wheeler-Jones C, Olsen I, Penny R, Black CM (1994) Circulating endothelin-1 levels in systemic sclerosis subsets-a marker of fibrosis or vascular dysfunction. J Rheumatol 21:1838-1844

    CAS  PubMed  Google Scholar 

  27. Springer TA (1990) Adhesion molecules of the immune system. Nature 346:425-433

    Article  CAS  PubMed  Google Scholar 

  28. Pigott R, Dillon LP, Hemingway IH, Gearing AJH (1992) Soluble forms of E-selectin, ICAM-1, and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cells. Biochem Biophys Res Commun 187:584-589

    Article  CAS  PubMed  Google Scholar 

  29. Gearing JH, Newman W (1993) Circulating adhesion molecules in disease. Immunology Today 14:506-512

    Article  CAS  PubMed  Google Scholar 

  30. Bevilaqua MP, Stengelin S, Gimbrone MA Jr, Seed B (1989) Endothelial leukocyte adhesion molecule 1: an inducible receptor for neutrophils related to complement regulatory proteins and lectins. Science 243:1160-1165

    Article  Google Scholar 

  31. Blann AD, Herrick A, Jayson MIV (1995) Altered levels of soluble adhesion molecules in rheumatoid arthritis, vasculitis, and systemic sclerosis. Br J Rheumatol 34:814-819

    Article  CAS  PubMed  Google Scholar 

  32. Claman HN, Giorno RC, Seibold JR (1991) Endothelial and fibroblast activation in scleroderma. Arthritis Rheum 34:1495

    Article  CAS  PubMed  Google Scholar 

  33. Gruschwitz MS, Hornstein OP, Von Den Driesch P (1995) Correlation of soluble adhesion molecules in the peripheral blood of scleroderma patients with their in-situ expression and with disease activity. Arthritis Rheum 38:184-189

    Article  CAS  PubMed  Google Scholar 

  34. Gruschwitz MS, Vieth G (1997) Up-regulation of class II major histocompatibility complex and intercellular adhesion molecule 1 expression on scleroderma fibroblasts and endothelial cells by interferon gamma and tumour necrosis factor alpha in the early disease stage. Arthritis Rheum 40:540-550

    Article  CAS  PubMed  Google Scholar 

  35. Jones SM, Mathew CM, Dixey J, Lovell CR, McHugh NJ (1996) VCAM-1 expression on endothelium in lesions from cutaneous lupus erythematosus is increased compared with systemic and localised scleroderma. Br J Dermatol 135:678-686

    Article  CAS  PubMed  Google Scholar 

  36. Sfikakis PP, Tesar J, Baraf H, Lipnick R, Klipple G, Tsokos GC (1993) Circulating ICAM-1 in patients with systemic sclerosis. Clin Immunol Immunopathol 68:88-92

    Article  CAS  PubMed  Google Scholar 

  37. Shi-Wen X, Panesar M, Vancheeswaran R, Mason J, Haskard DO, Black CM, Olsen IO, Abraham DJ (1994) Expression and shedding of ICAM-1 and LFA-3 by scleroderma and normal fibroblasts. Arthritis Rheum 37:1689-1697

    Article  CAS  PubMed  Google Scholar 

  38. Solberg S, Peltonen J, Uitto J, Jiminez S (1992) Elevated expression of beta 1 and beta 2 integrins, intercellular adhesion molecule 1, and endothelial leukocyte adhesion molecule 1 in the skin of patients with systemic sclerosis of recent onset. Arthritis Rheum 35:290-298

    Article  Google Scholar 

  39. Stratton RJ, Coghlan JG, Pearson JD, Burns A, Sweny P, Abraham DJ, Black CM (1998) Different patterns of endothelial cell activation in renal and pulmonary vascular disease in scleroderma. QJM 91(8):561-566

    Article  CAS  PubMed  Google Scholar 

  40. Apras S, Ertenli I, Ozbalkan Z, Kiraz S, Ozturk MA, Haznedaroglu IC, Cobankara V, Pay S, Calguneri M (2003) Effects of oral cyclophosphamide and prednisolone therapy on the endothelial functions and clinical findings in patients with early diffuse systemic sclerosis. Arthritis Rheum 48:2256-2261

    Article  CAS  PubMed  Google Scholar 

  41. Pober JS, Bevilacqua MP, Mendrick DL, Lapieree LA, Fiers W, Gimbrone MA (1986) Two distinct monokines interleukin-1 and tumour necrosis factor, each independently induce biosynthesis and transient expression of the same antigen on the surface of the same antigen on the surface of cultured human vascular endothelial cells. J Immunol 136:1680-1687

    CAS  PubMed  Google Scholar 

  42. Hakkert BC, Kuijpers TW, Leeuwenberg JF, Van Mourik JA, Roos D (1991) Neutrophil and monocyte adherence to and migration across monolayers of cytokine activated endothelial cells: the contribution of CD 18, ELAM-1, and VLA-4. Blood 78:2721-2726

    CAS  PubMed  Google Scholar 

  43. Picker LJ, Warnock RA, Burns AR, Doerschuk CM, Berg EL, Butcher EC (1991) The neutrophil selectin LECAM-1 presents carbohydrate ligands to the vascular selectins ELAM-1 and GMP-140. Cell 66:921-933

    Article  CAS  PubMed  Google Scholar 

  44. Shimuzu Y, Newman W, Gopal TV, Horgan KJ, Graber N, Beall LD, van Seventer GA, Shaw S (1991) Four molecular pathways of T cell adhesion to endothelial cells: roles of LFA-1, VCAM-1, and ELAM-1 and changes in pathway hierarchy under different activation conditions. J Cell Biol 113:1203-1212

    Article  Google Scholar 

  45. Ghilardi G, Biondi ML, Turri O, Guagnellini E, Scorza R (2004) Ser128Arg gene polymorphism for E-selectin and severity of atherosclerotic arterial disease. J Cardiovasc Surg (Torino) 45:143-147

    CAS  Google Scholar 

  46. Rauchhaus M, Gross M, Schulz S et al (2002) The E-selectin SER128ARG gene polymorphism and restenosis after successful coronary angioplasty. Int J Cardiol 83:249-257

    Article  PubMed  Google Scholar 

  47. Boehme MWJ, Schmitt WH, Youinou P, Stremmel WR, Gross WL (1996) Clinical relevance of elevated serum thrombomodulin and soluble E-selectin in patients with Wegener’s granulomatosis and other systemic vasculitides. Am J Med 101:387-394

    Article  CAS  PubMed  Google Scholar 

  48. Dittman WA, Majerus PW (1990) Structure and function of thrombomodulin: a natural anticoagulant. Blood 75:329-336

    CAS  PubMed  Google Scholar 

  49. Ishi H, Majerus PW (1985) Thrombomodulin is present in human serum and urine. J Clin Invest 76:2178-2184

    Article  Google Scholar 

  50. Chaouat A, Weitzenblum E, Higenbottam T (1996) The role of thrombosis in severe pulmonary hypertension. Eur Resp J 9:356-363

    Article  CAS  Google Scholar 

  51. Eisenberg PR, Lucore C, Kaufman L, Sobel BE, Jaffe AS, Rich S (1990) Fibrinopeptide A levels indicative of pulmonary vascular thrombosis in patients with primary pulmonary hypertension. Circulation 82:841-847

    CAS  PubMed  Google Scholar 

  52. Cacoub P, Karmochkine M, Dorent R, Nataf P, Piette JC, Godeu P, Gandjbakhch I, Boffa MC (1996) Plasma levels of thrombomodulin in pulmonary hypertension. Am J Med 101:160-164

    Article  CAS  PubMed  Google Scholar 

  53. Welsh CH, Hassell KL, Badesh DB, Kressin DC, Marlar RA (1996) Coagulation and fibrinolytic profiles in patients with severe pulmonary hypertension. Chest 110:710-717

    Article  CAS  PubMed  Google Scholar 

  54. Stratton RJ, Pompon L, Coghlan JG, Pearson JD, Black CM (2000) Soluble thrombomodulin concentration is raised in scleroderma associated pulmonary hypertension. Ann Rheum Dis 59:132-134

    Article  CAS  PubMed  Google Scholar 

  55. Ishii H, Uchiyama H, Kazama M (1991) Soluble thrombomodulin antigen in conditioned medium is increased by damage of endothelial cells. Thromb Haemost 65:618-623

    CAS  PubMed  Google Scholar 

  56. Malek AM, Jackman R, Rosenberg RD, Izumo S (1994) Endothelial expression of thrombomodulin is reversibly regulated by fluid shear stress. Clin Res 74:852-860

    CAS  Google Scholar 

  57. Shreeniwas R, Ogawa S, Cozzolino F, Torcia G, Braunstein N, Butura C, Brett J, Lieberman HB, Furie MB, Joseph-Silverstein J (1991) Macrovascular and microvascular endothelium during long term hypoxia: alterations in cell growth, monolayer permeability, and cell surface coagulant properties. J Cell Physiol 146:8-17

    Article  CAS  PubMed  Google Scholar 

  58. Shreeniwas R, Ogawa S, Cozzolino F, Torcia G, Braunstein N, Butura C et al (1991) Macrovascular and microvascular endothelium during long term hypoxia: alterations in cell growth, monolayer permeability, and cell surface coagulant properties. J Cell Physiol 146:8-17

    Article  CAS  PubMed  Google Scholar 

  59. Cohen S, Johnson R, Hurd E (1983) Cytotoxicity of sera from patients with scleroderma. Effects on human endothelial cells and fibroblasts in culture. Arthritis Rheum 26:170-178

    Article  CAS  PubMed  Google Scholar 

  60. Blake DR, Winyard P, Scott DGI, Brailsford S, Blann A, Lunec J (1991) Endothelial cell cytotoxicity in inflammatory vascular diseases-the possible role of oxidised lipoproteins. Ann Rheum Dis 44:176-182

    Article  Google Scholar 

  61. Blann AD, Illingworth K, Jayson MI (1993) Mechanisms of endothelial cell damage in systemic sclerosis and Raynaud’s phenomenon. J Rheumatol 20(8):1325-1330

    CAS  PubMed  Google Scholar 

  62. Lindqvist RJ, Osterland CK (1971) Human antibodies to vascular endothelium. Clin Exp Immunol 9:753-760

    CAS  PubMed  Google Scholar 

  63. Cervera R, Khamashta MA, Hughes GRV (1993) Antibodies to endothelial cells and vascular damage. CRC Press, Boca Raton, FL, pp 83-184

    Google Scholar 

  64. Del Papa N, Conforti G, Gambini D, La Rosa L, Tincani A, D’Cruz D, Khamashta M, Hughes GRV, Balastriere G (1994) and Meroni PL Characterisation of the endothelial surface proteins recognised by anti endothelial antibodies in primary and secondary autoimmune vasculitis. Clin Immunol Immunopathol 70:211-216

    Article  PubMed  Google Scholar 

  65. Del Papa N, Gambini D, Meroni PL (1994) Anti-endothelial cell antibodies in autoimmune disease. Clin Rev Allergy 12:275-286

    PubMed  Google Scholar 

  66. Hashemi S, Smith CD, Izaguirre CA (1987) Anti-endothelial cell antibodies: detection and characterisation using a cellular enzyme-linked immunosorbent assay. J Lab Clin Med 109:434-440

    CAS  PubMed  Google Scholar 

  67. Holt CM, Lindsey N, Moult J, Malia RG, Greaves M, Hume A, Rowell N, Hughes P (1989) Antibody-dependent cellular cytotoxicity of vascular endothelium: characterisation and pathogenic associations in systemic sclerosis. Clin Exp Immunol 78:359-365

    CAS  PubMed  Google Scholar 

  68. Penning CA, Cunningham J, French MAH, Harrison G, Rowell NR, Hughes P (1984) Antibody dependent cytotoxicity of human vascular endothelium in systemic sclerosis. Clin Exp Immunol 57:548-556

    CAS  PubMed  Google Scholar 

  69. Rosenbaum JR, Pottinger BE, Woo P, Black CM, Byron MA, Pearson JD (1988) Measurement and characterisation of circulating anti-endothelial cell IgG in connective tissue diseases. Clin Exp Immunol 72:450-456

    CAS  PubMed  Google Scholar 

  70. Carvalho D, Savage CO, Black CM, Pearson JD (1996) IgG antiendothelial cells from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro. Induction of adhesion molecule expression and involvement of endothelium derived cytokines. J Clin Invest 97:111-119

    Article  CAS  PubMed  Google Scholar 

  71. Sgonc R, Gruschwitz MS, Boeck G, Sepp N, Gruber J, Wick G (2000) Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95. Arthritis Rheum 43(11):2550-2562

    Article  CAS  PubMed  Google Scholar 

  72. Van Der Zee JM, Seigert CEH, De Vreede TA, Daha MR, Breedveld FC (1991) Characterisation of anti-endothelial cell antibodies in systemic lupus erythematosus. Clin exp Immunol 84:238-244

    Article  PubMed  Google Scholar 

  73. Tuffanelli DL, Winkelmann RF (1961) Systemic scleroderma : a clinical study of 727 cases. Arch Dermatol 84:359-371

    CAS  PubMed  Google Scholar 

  74. Wigley FM (1993) Raynaud’s phenomenon. Curr Opin Rheumatol 5:773-784

    Article  CAS  PubMed  Google Scholar 

  75. D’Angelo WA, Fries JF, Masi AT, Shulman LE (1969) Pathologic observations in systemic sclerosis. A study of fifty eight autopsy cases and fifty eight matched controls. Am J Med 46:428-440

    Article  PubMed  Google Scholar 

  76. Young RH, Mark GJ (1978) Pulmonary vascular changes in scleroderma. Am J Med 64:998-1004

    Article  CAS  PubMed  Google Scholar 

  77. Rubin LJ (1993) Primary pulmonary hypertension. Chest 104:236-250

    Article  CAS  PubMed  Google Scholar 

  78. Salerni R, Rodnan GP, Leon DF (1984) Shaver JA Pulmonary hypertension in the CREST syndrome variant of progressive systemic sclerosis (scleroderma). Ann Intern Med 86:394-399

    Google Scholar 

  79. Stupi AM, Steen VD, Owens GR, Barnes EL, Rodnan GP, Medsger TA Jr (1986) Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum 29:515-524

    Article  CAS  PubMed  Google Scholar 

  80. Al-Sabbagh MR, Steen VD, Zee BC, Nalesnik M, Trostle DC, Bedetti CD, Medsger TA Jr (1989) Pulmonary artery histology and morphometry in systemic sclerosis: a case-control autopsy study. J Rheumatol 16:1038-1042

    CAS  PubMed  Google Scholar 

  81. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesh D, Groves B, Tapson VF, Barge RC, Brundage BH, Koerner SK, Langleben D, Keller CA, Murali S, Uretsky BF, Clayton LM, Jobsis MM, Blackburn SD, Shortino D, Crow JW (1996) A comparison of continuous intravenous epoprostinol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 334:296-301

    Article  CAS  PubMed  Google Scholar 

  82. Rodnan GP, Benedek TG (1962) An historical account of the study of progressive systemic sclerosis(diffuse scleroderma). Ann Intern Med 57:305-319

    CAS  PubMed  Google Scholar 

  83. Shapiro AP, Medsger TA. Renal Involvment in Systemic Sclerosis. In Diseases of the Kidney.4th ed. Schreiner R and Gottschalk C, eds. USA: Little, Brown; 1988:2273-2283

    Google Scholar 

  84. Cannon PJ, Hassar M, Case DB, Casarella WJ, Sommers SC, LeRoy EC (1974) The relationship of hypertension and renal failure in scleroderma to structural and functional abnormalities of the renal cortical circulation. Medicine 53:1-46

    Article  CAS  PubMed  Google Scholar 

  85. Trostle DC, Bedetti CD, Steen VD, Al-Sabbagh MR, Zee B, Medsger TA Jr (1988) Renal vascular histology and morphometry in systemic sclerosis. A case-control autopsy study. Arthritis Rheum 31:393-400

    Article  CAS  PubMed  Google Scholar 

  86. Traub YM, Shapiro AP, Rodnan GP, Medsger TA, McDonald RH, Steen VD, Osial T Jr, Tolchin SR (1983) Hypertension and renal failure (scleroderma renal crisis) in progressive systemic sclerosis. Medicine 62:335-352

    Article  CAS  PubMed  Google Scholar 

  87. Medsger TA, Masi AT, Rodnan GP, Benedek TG, Robinson H (1971) Survival with systemic sclerosis. Ann Int Med 75:369-376

    PubMed  Google Scholar 

  88. Steen VD, Costantino JP, Shapiro AP, Medsger TA (1990) Outcome of renal crisis in systemic sclerosis:relation to the availability of angiotensin converting enzyme inhibitors. Ann Int Med 113:352-357

    CAS  PubMed  Google Scholar 

  89. Beckett VL, Donadio JV, Brennan LA, Comm DL, Osmundson PJ, Chao EY, Holley KE (1985) Use of captopril as early therapy for renal scleroderma: a prospective study. Mayo Clin Proc 60:763-771

    CAS  PubMed  Google Scholar 

  90. Palmer RM, Ashton DS, Moncada S (1988) Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 333:664-666

    Article  CAS  PubMed  Google Scholar 

  91. DeWitt DL, Day JS, Sonnenburg WK, Smith WL (1983) Concentrations of prostaglandin endoperoxide synthase and prostaglandin I2 synthase in the endothelium and smooth muscle of bovine aorta. J Clin Invest 72:1882-1888

    Article  CAS  PubMed  Google Scholar 

  92. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T (1988) A novel potent vasoconstrictor peptide produced by endothelial cells. Nature 332:411-415

    Article  CAS  PubMed  Google Scholar 

  93. Takagi K, Kawaguchi Y, Hara M, Sugiura T, Harigai M, Kamatani N (2003) Serum nitric oxide (NO) levels in systemic sclerosis patients: correlation between NO levels and clinical features. Clin Exp Immunol 134:538-544

    Article  CAS  PubMed  Google Scholar 

  94. Yamamoto T, Katayama I, Nishioka K (1998) Nitric oxide production and inducible nitric oxide synthase expression in systemic sclerosis. J Rheumatol 25(2):314-317

    CAS  PubMed  Google Scholar 

  95. Romero LI, Zhang DN, Cooke JP, Ho HK, Avalos E, Herrera R, Herron GS (2000) Differential expression of nitric oxide by dermal microvascular endothelial cells from patients with scleroderma. Vasc Med 5(3):147-158

    CAS  PubMed  Google Scholar 

  96. Cotton SA, Herrick AL, Jayson MI, Freemont AJ (1999) Endothelial expression of nitric oxide synthases and nitrotyrosine in systemic sclerosis skin. J Pathol 189:273-278

    Article  CAS  PubMed  Google Scholar 

  97. Belch JJ, McLaren M, Anderson J, Lowe GD, Sturrock RD, Capell HA, Forbes CD (1985) Increased prostacyclin metabolites and decreased red cell deformability in patients with systemic sclerosis and Raynauds syndrome. Prostaglandins Leukot Med 17:1-9

    Article  CAS  PubMed  Google Scholar 

  98. Stratton R, Shiwen X, Martini G, Holmes A, Leask A, Haberberger T, Martin GR, Black CM, Abraham D (2001) Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. J Clin Invest 108:241-250

    CAS  PubMed  Google Scholar 

  99. Tuder RM, Cool CD, Geraci MW, Wang J, Abman SH, Wright L, Badesch D, Voelkel NF (1999) Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 159(6):1925-1932

    CAS  PubMed  Google Scholar 

  100. Klimiuk PS, Taylor L, Baker RD, Jayson MI (1988) Autonomic neuropathy in systemic sclerosis. Ann Rheum Dis 47(7):542-545

    Article  CAS  PubMed  Google Scholar 

  101. Bunker CB, Terenghi G, Springall DR, Polak JM, Dowd PM (1990) Deficiency of calcitonin gene-related peptide in Raynaud’s phenomenon. Lancet 336(8730):1530-1533

    Article  CAS  PubMed  Google Scholar 

  102. Chotani MA, Flavahan S, Mitra S, Daunt D, Flavahan NA (2000) Silent alpha(2C)-adrenergic receptors enable cold-induced vasoconstriction in cutaneous arteries. Am J Physiol Heart Circ Physiol 278(4):H1075-H1083

    CAS  PubMed  Google Scholar 

  103. Flavahan NA, Flavahan S, Liu Q, Wu S, Tidmore W, Wiener CM, Spence RJ, Wigley FM (2000) Increased α2-adrenergic constriction of isolated arterioles in diffuse scleroderma. Arthritis Rheum 43:1886-1890

    Article  CAS  PubMed  Google Scholar 

  104. Kuryliszyn-Moskal A, Klimiuk PA, Sierakowski S (2005) Soluble adhesion molecules (sVCAM-1, sE-selectin), vascular endothelial growth factor (VEGF) and endothelin-1 in patients with systemic sclerosis: relationship to organ systemic involvement. Clin Rheumatol 24(2):111-116

    Article  PubMed  Google Scholar 

  105. Danese C, Parlapiano C, Zavattaro E, Di Prima M, Campana E, Rota C, Tonnarini G, Di Siena G, Borgia MC (1997) ET-1 plasma levels during cold stress test in sclerodermic patients. Angiology 48(11):965-968

    Article  CAS  PubMed  Google Scholar 

  106. Tabata H, Yamakage A, Yamazaki S (1997) Cutaneous localization of endothelin-1 in patients with systemic sclerosis: immunoelectron microscopic study. Int J Dermatol 36(4):272-275

    Article  CAS  PubMed  Google Scholar 

  107. Shi-Wen X, Chen Y, Denton CP, Eastwood M, Renzoni EA, Bou-Gharios G, Pearson JD, Dashwood M, du Bois RM, Black CM, Leask A, Abraham DJ (2004) Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Mol Biol Cell 15(6):2707-2719

    Article  PubMed  Google Scholar 

  108. Hettema ME, Zhang D, Bootsma H, Kallenberg CG (2007) Bosentan therapy for patients with severe Raynaud’s phenomenon in systemic sclerosis. Ann Rheum Dis 66(10):1398-1399

    Article  CAS  PubMed  Google Scholar 

  109. Riccardi MT, Chialà A, Lannone F, Grattagliano V, Covelli M, Lapadula G (2007) Treatment of digital ulcers in systemtic sclerosis with endothelin-1 receptor antagonist (bosentan). Reumatismo 59(2):135-139

    CAS  PubMed  Google Scholar 

  110. Williamson DJ, Wallman LL, Jones R, Keogh AM, Scroope F, Penny R, Weber C, Macdonald PS (2000) Hemodynamic effects of Bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension. Circulation 102(4):411-418

    CAS  PubMed  Google Scholar 

  111. Denton CP, Humbert M, Rubin L, Black CM (2006) Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis 65(10):1336-1340

    Article  CAS  PubMed  Google Scholar 

  112. Finch MB, Dawson J, Johnston GD (1986) The peripheral vascular effects of nifedipine in Raynaud’s syndrome associated with scleroderma: a double blind crossover study. Clin Rheumatol 5:493-498

    CAS  PubMed  Google Scholar 

  113. de la Mata J, Gomez-Sanchez MA, Aranzana M, Gomez-Reino JJ (1994) Long term iloprost infusion therapy for severe pulmonary hypertension in patients with connective tissue diseases. Arthritis Rheum 37:1528-1533

    Article  PubMed  Google Scholar 

  114. Kyle MV, Belcher G, Hazleman BL (1992) Placebo-controlled study showing therapeutic benefit of Iloprost in the treatment of Raynaud’s phenomenon. J Rheumatol 19:1403-1406

    CAS  PubMed  Google Scholar 

  115. Rademaker M, Cooke ED, Almond NE, Beacham JA, Smith RE, Mant TG, Kirby JD (1989) Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud’s phenomenon in patients with systemic sclerosis: a double blind randomised study. BMJ 298(6673):561-564

    Article  CAS  PubMed  Google Scholar 

  116. Sinzinger H, Zidek T, Fitscha P, O’Grady J, Wagner O, Kaliman J (1987) Prostaglandin I2 reduces activation of human arterial smooth muscle cells in-vivo. Prostaglandins 33(6):915-918

    Article  CAS  PubMed  Google Scholar 

  117. Weber AA, Zucker TP, Hasse A, Bönisch D, Wittpoth M, Schrör K (1998) Antimitogenic effects of vasodilatory prostaglandins in coronary artery smooth muscle cells. Basic Res Cardiol 93(3):54-57

    Article  CAS  PubMed  Google Scholar 

  118. Lin H, Lee JL, Hou HH, Chung CP, Hsu SP, Juan SH (2008) Molecular mechanisms of the antiproliferative effect of beraprost, a prostacyclin agonist, in murine vascular smooth muscle cells. J Cell Physiol 214(2):434-441

    Article  CAS  PubMed  Google Scholar 

  119. Rybalkin S, Yan C, Bornfeldt K, Beavo J (2003) Cyclic GMP phosphodiesterases and regulation of smooth muscle function. Circ Res 93:280-291

    Article  CAS  PubMed  Google Scholar 

  120. Hayakawa I, Shirasaki F, Hirano T, Oishi N, Hasegawa M, Sato S, Takehara K (2006) Successful treatment with sildenafil in systemic sclerosis patients with isolated pulmonary arterial hypertension: two case reports. Rheumatol Int 26(3):270-273

    Article  PubMed  Google Scholar 

  121. Gore J, Silver R (2005) Oral sildenafil for the treatment of Raynaud’s phenomenon and digital ulcers secondary to systemic sclerosis. Ann Rheum Dis 64(9):1387

    Article  CAS  PubMed  Google Scholar 

  122. Badesch DB, Hill NS, Burgess G, Rubin LJ, Barst RJ, Galiè N (2007) Simonneau G Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol 34(12):2417-2422

    PubMed  Google Scholar 

  123. Tantini B, Manes A, Fiumana E et al (2005) Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells. Basic Res Cardiol 100:131-138

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre for Rheumatology, The Royal Free Hospital, London, UK

    Anna Nuttall, Emma Derrett-Smith & Richard Stratton

Authors
  1. Anna Nuttall
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Emma Derrett-Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Richard Stratton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Richard Stratton .

Editor information

Editors and Affiliations

  1. University College London, Gower Street, London, WC1E 6BT, United Kingdom

    David Abraham

  2. The Royal Free & Univ College Med School, Gower Street, London, WC1E 6BT, United Kingdom

    Handler Clive

  3. University College London, Gower Street, London, WC1E 6BT, United Kingdom

    Michael Dashwood

  4. The Royal Free & Univ College Med School, Gower Street, London, WC1E 6BT, United Kingdom

    Gerry Coghlan

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer-Verlag London

About this chapter

Cite this chapter

Nuttall, A., Derrett-Smith, E., Stratton, R. (2009). Advances in Vascular Medicine. In: Abraham, D., Clive, H., Dashwood, M., Coghlan, G. (eds) Advances in Vascular Medicine. Springer, London. https://doi.org/10.1007/978-1-84882-637-3_19

Download citation

  • DOI: https://doi.org/10.1007/978-1-84882-637-3_19

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-84882-636-6

  • Online ISBN: 978-1-84882-637-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation